DBV Technologies (DBVT) shares fell 1.5% in recent Monday trading after the company reported that full-year 2024 losses widened to $1.17 per diluted share from $0.76 a year earlier.
A single analyst polled by FactSet expected a loss of $0.98.
As expected, no revenue for the year ended Dec. 31 was reported.
As of Dec. 31, the company said it had $32.5 million in cash and cash equivalents, and expected it could fund operations through April.
The company also announced the US Food and Drug Administration agreed with its proposal to consider the safety exposure data from the Vitesse Phase 3 study for Viaskin peanut patch in children aged four to seven years for a biologics license application filing in this age group.
This expedites the submission of the application to H1 2026 and accelerates the potential launch of the product by a year if approved. The FDA's decision also eliminates the need to conduct the Comfort Children supplemental safety study, the company said.
Price: 4.54, Change: -0.07, Percent Change: -1.52
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.